The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

Yevgeniy Balagula; Steven T. Rosen; Mario E. Lacouture

doi:10.1016/j.jaad.2010.06.051

The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

Yevgeniy Balagula, Steven T. Rosen, Mario E. Lacouture

Research output: Contribution to journal › Review article › peer-review

66 Scopus citations

Abstract

Cancer therapies have led to remarkable results due to improved toxicity profiles and effects on survival. While these medical, surgical, and radiation protocols are chiefly responsible for these noteworthy contributions, an unexpected constellation of toxicities has emerged. Most notably, dermatologic adverse events have gained considerable attention, due to their high frequency, visibility, and impact on physical and psychosocial health, all of which affect dose intensity and possibly clinical outcome. Consequently, increased attention to cutaneous health in oncology has resulted in supportive oncodermatology clinical programs and toxicity-driven investigations, aiming to mitigate these untoward events and permit the continued optimization of cancer treatments.

Original language	English (US)
Pages (from-to)	624-635
Number of pages	12
Journal	Journal of the American Academy of Dermatology
Volume	65
Issue number	3
DOIs	https://doi.org/10.1016/j.jaad.2010.06.051
State	Published - Sep 1 2011
Externally published	Yes

Keywords

CIA
EGFR
EGFRI
FDA
Food and Drug Administration
HFS
HFSR
MASCC
Multinational Association for Supportive Care in Cancer
QoL
RCT
chemotherapy-induced alopecia
epidermal growth factor receptor
epidermal growth factor receptor inhibitor
hand-foot skin reaction
hand-foot syndrome
quality of life
randomized controlled trial

ASJC Scopus subject areas

Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jaad.2010.06.051

Cite this

@article{c9f8c24fbf36470bb0fd4a2e669830ee,

title = "The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies",

abstract = "Cancer therapies have led to remarkable results due to improved toxicity profiles and effects on survival. While these medical, surgical, and radiation protocols are chiefly responsible for these noteworthy contributions, an unexpected constellation of toxicities has emerged. Most notably, dermatologic adverse events have gained considerable attention, due to their high frequency, visibility, and impact on physical and psychosocial health, all of which affect dose intensity and possibly clinical outcome. Consequently, increased attention to cutaneous health in oncology has resulted in supportive oncodermatology clinical programs and toxicity-driven investigations, aiming to mitigate these untoward events and permit the continued optimization of cancer treatments.",

keywords = "CIA, EGFR, EGFRI, FDA, Food and Drug Administration, HFS, HFSR, MASCC, Multinational Association for Supportive Care in Cancer, QoL, RCT, chemotherapy-induced alopecia, epidermal growth factor receptor, epidermal growth factor receptor inhibitor, hand-foot skin reaction, hand-foot syndrome, quality of life, randomized controlled trial",

author = "Yevgeniy Balagula and Rosen, {Steven T.} and Lacouture, {Mario E.}",

year = "2011",

month = sep,

day = "1",

doi = "10.1016/j.jaad.2010.06.051",

language = "English (US)",

volume = "65",

pages = "624--635",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "3",

}

TY - JOUR

T1 - The emergence of supportive oncodermatology

T2 - The study of dermatologic adverse events to cancer therapies

AU - Balagula, Yevgeniy

AU - Rosen, Steven T.

AU - Lacouture, Mario E.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Cancer therapies have led to remarkable results due to improved toxicity profiles and effects on survival. While these medical, surgical, and radiation protocols are chiefly responsible for these noteworthy contributions, an unexpected constellation of toxicities has emerged. Most notably, dermatologic adverse events have gained considerable attention, due to their high frequency, visibility, and impact on physical and psychosocial health, all of which affect dose intensity and possibly clinical outcome. Consequently, increased attention to cutaneous health in oncology has resulted in supportive oncodermatology clinical programs and toxicity-driven investigations, aiming to mitigate these untoward events and permit the continued optimization of cancer treatments.

AB - Cancer therapies have led to remarkable results due to improved toxicity profiles and effects on survival. While these medical, surgical, and radiation protocols are chiefly responsible for these noteworthy contributions, an unexpected constellation of toxicities has emerged. Most notably, dermatologic adverse events have gained considerable attention, due to their high frequency, visibility, and impact on physical and psychosocial health, all of which affect dose intensity and possibly clinical outcome. Consequently, increased attention to cutaneous health in oncology has resulted in supportive oncodermatology clinical programs and toxicity-driven investigations, aiming to mitigate these untoward events and permit the continued optimization of cancer treatments.

KW - CIA

KW - EGFR

KW - EGFRI

KW - FDA

KW - Food and Drug Administration

KW - HFS

KW - HFSR

KW - MASCC

KW - Multinational Association for Supportive Care in Cancer

KW - QoL

KW - RCT

KW - chemotherapy-induced alopecia

KW - epidermal growth factor receptor

KW - epidermal growth factor receptor inhibitor

KW - hand-foot skin reaction

KW - hand-foot syndrome

KW - quality of life

KW - randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=80051798682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051798682&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2010.06.051

DO - 10.1016/j.jaad.2010.06.051

M3 - Review article

C2 - 21777992

AN - SCOPUS:80051798682

SN - 0190-9622

VL - 65

SP - 624

EP - 635

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 3

ER -

The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this